50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
NASDAQ:BCRX

BioCryst Pharmaceuticals - BCRX Stock Forecast, Price & News

$12.36
-0.34 (-2.68%)
(As of 09/23/2022 08:55 PM ET)
Add
Compare
Today's Range
$12.03
$12.61
50-Day Range
$10.79
$14.81
52-Week Range
$7.61
$19.99
Volume
2.26 million shs
Average Volume
3.89 million shs
Market Capitalization
$2.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.86

BioCryst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
36.4% Upside
$16.86 Price Target
Short Interest
Bearish
15.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.23) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

881st out of 1,075 stocks

Biological Products, Except Diagnostic Industry

141st out of 172 stocks

BCRX stock logo

About BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BCRX Stock News Headlines

BioCryst Pharmaceuticals (NASDAQ: BCRX)
See More Headlines
Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BCRX Company Calendar

Last Earnings
8/04/2022
Today
9/25/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BCRX
CUSIP
09058V10
Employees
358
Year Founded
1986

Price Target and Rating

Average Stock Price Forecast
$16.86
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+36.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-184,060,000.00
Net Margins
-102.96%
Pretax Margin
-101.30%

Debt

Sales & Book Value

Annual Sales
$157.17 million
Book Value
($0.60) per share

Miscellaneous

Free Float
176,648,000
Market Cap
$2.30 billion
Optionable
Optionable
Beta
2.08

Social Links


Key Executives

  • Mr. Jon P. StonehouseMr. Jon P. Stonehouse (Age 61)
    CEO, Pres & Exec. Director
    Comp: $1.14M
  • Mr. Anthony J. DoyleMr. Anthony J. Doyle (Age 42)
    Sr. VP & CFO
    Comp: $745.79k
  • Dr. William P. SheridanDr. William P. Sheridan (Age 67)
    Chief Medical Officer & Sr. VP
    Comp: $843.42k
  • Dr. Yarlagadda S. BabuDr. Yarlagadda S. Babu (Age 69)
    Chief Discovery Officer
    Comp: $698.33k
  • Dr. Helen M. Thackray FAAP (Age 54)
    M.D., Chief R&D Officer
    Comp: $966.38k
  • Mr. Michael L. Jones (Age 52)
    Exec. Director of Fin. & Principal Accounting Officer
  • Ms. Alane P. BarnesMs. Alane P. Barnes (Age 56)
    Sr. VP, Chief Legal Officer & Corp. Sec.
  • Mr. John D. Bluth (Age 49)
    Chief Communications Officer
  • Ms. Stephanie Angelini
    Chief People Officer
  • Dr. Elliott T. Berger
    Sr. VP of Regulatory Affairs













BCRX Stock - Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BCRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCRX, but not buy additional shares or sell existing shares.
View BCRX analyst ratings
or view top-rated stocks.

What is BioCryst Pharmaceuticals' stock price forecast for 2022?

8 equities research analysts have issued twelve-month target prices for BioCryst Pharmaceuticals' stock. Their BCRX share price forecasts range from $13.00 to $30.00. On average, they predict the company's stock price to reach $16.86 in the next twelve months. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for BCRX
or view top-rated stocks among Wall Street analysts.

How have BCRX shares performed in 2022?

BioCryst Pharmaceuticals' stock was trading at $13.85 at the beginning of 2022. Since then, BCRX stock has decreased by 10.8% and is now trading at $12.36.
View the best growth stocks for 2022 here
.

When is BioCryst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our BCRX earnings forecast
.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. During the same period last year, the business posted ($0.24) earnings per share.

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

What other stocks do shareholders of BioCryst Pharmaceuticals own?
What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (5.92%), Pictet Asset Management SA (3.26%), FMR LLC (2.79%), Victory Capital Management Inc. (2.46%), Assenagon Asset Management S.A. (1.71%) and Artisan Partners Limited Partnership (1.57%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends
.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $12.36.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $2.30 billion and generates $157.17 million in revenue each year. The biotechnology company earns $-184,060,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

The company employs 358 workers across the globe.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314.

This page (NASDAQ:BCRX) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.